Core Insights - BioSyent Inc. reported strong financial performance for Q2 and H1 2025, with overall sales growth of 14% and net profit growth of 28% [1][5] - The Canadian Pharma segment saw a 9% increase in sales, while the International Pharma segment experienced a significant 183% increase in Q2 2025 [1][5] - The company aims for long-term value creation through portfolio diversification and profitable growth [1] Financial Performance - Total Company Sales for Q2 2025 reached CAD 10,179,296, a 14% increase compared to Q2 2024, and CAD 21,158,256 for H1 2025, reflecting a 27% increase from H1 2024 [5][9] - Net Income After Taxes for Q2 2025 was CAD 2,018,171, up 28% from Q2 2024, and CAD 4,338,104 for H1 2025, a 30% increase from H1 2024 [5][9] - EBITDA for Q2 2025 was CAD 2,760,149, representing a 35% increase year-over-year, and CAD 5,961,796 for H1 2025, a 40% increase [5][9] Balance Sheet Highlights - As of June 30, 2025, total assets increased to CAD 43,495,489, a 5% rise from December 31, 2024 [7][10] - Cash, cash equivalents, and short-term investments rose by 28% to CAD 20,364,392 [7] - Trade and other receivables increased by 67% to CAD 4,867,796, while inventory decreased by 9% to CAD 4,860,613 [7] Shareholder Returns - The company repurchased 19,500 common shares during H1 2025 under a Normal Course Issuer Bid [5] - Quarterly cash dividends of CAD 0.05 per common share were paid on March 14, 2025, and June 13, 2025, with a subsequent dividend declared for September 15, 2025 [5]

Financial Performance - BioSyent Inc. reported a total company sales of CAD 10,978,960 for Q1 2025, representing a 42% increase compared to Q1 2024 [1][7] - Canadian Pharma sales reached CAD 9,159,652, up 21% year-over-year, while International Pharma sales surged by 135% to CAD 1,535,216 [1][7] - EBITDA for Q1 2025 was CAD 3,201,647, reflecting a 45% increase from the previous year, with a consistent EBITDA margin of 29% [1][7] - Net Income After Taxes (NIAT) was CAD 2,319,933, a 31% increase compared to Q1 2024, with a fully diluted EPS of CAD 0.20, up 35% [1][7] Product Performance - FeraMAX Pd sales grew by 18% in Q1 2025, bolstered by its recognition as the 1 recommended OTC oral iron supplement in Canada for the tenth consecutive year [2] - Tibella (tibolone) product sales increased by 53% in Canada, with improved gross margins following the acquisition of worldwide rights in September 2024 [2] - The first international shipments of Tibelia generated new revenues of CAD 0.8 million in Q1 2025, with further deliveries planned throughout the year [2] Corporate Developments - Mr. Prakash Gowd was elected to the Board of Directors, replacing Mr. Larry Andrews, who retired after seven years of service [2] - The company repurchased 19,500 common shares under its Normal Course Issuer Bid (NCIB) during Q1 2025 [3] - A quarterly cash dividend of CAD 0.05 per common share was paid on March 14, 2025, with a subsequent dividend declared for June 13, 2025 [3] Financial Position - As of March 31, 2025, total assets increased to CAD 42,762,182, a 3% rise from December 31, 2024 [8][9] - Current assets rose by 17% to CAD 28,642,114, driven by an 87% increase in trade and other receivables [8][9] - Total equity also grew by 3% to CAD 36,011,796, indicating a stable financial position [8][9]